CERo Therapeutics Holdings, Inc.
CERO
$5.40
-$0.10-1.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 41.99% | 56.67% | 136.16% | 126.46% | 51.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.86% | 74.10% | 115.72% | 98.35% | 77.13% |
| Operating Income | -37.86% | -74.10% | -115.72% | -98.35% | -77.13% |
| Income Before Tax | -91.22% | -58.57% | -16.22% | -82.75% | -79.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -91.22% | -58.57% | -16.22% | -66.73% | -56.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -91.22% | -58.57% | -16.22% | -66.73% | -56.36% |
| EBIT | -37.86% | -74.10% | -115.72% | -98.35% | -77.13% |
| EBITDA | -40.18% | -78.44% | -123.60% | -144.43% | -157.48% |
| EPS Basic | -101.26% | -168.04% | -334.46% | -191.83% | -116.64% |
| Normalized Basic EPS | -293.07% | -276.68% | -- | -306.99% | -194.19% |
| EPS Diluted | -101.26% | -168.04% | -334.46% | -191.83% | -116.64% |
| Normalized Diluted EPS | -293.07% | -276.68% | -- | -306.99% | -194.19% |
| Average Basic Shares Outstanding | 15,503.17% | 14,215.30% | -- | 153.40% | -91.80% |
| Average Diluted Shares Outstanding | 1,893.80% | 1,039.40% | 187.18% | -32.36% | -67.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |